Moderna stock jumps after cancer vaccine signals

Merck and Moderna announced positive results from a new personalized vaccine trial for high-risk melanoma skin cancer. The promising results came from Phase 3 clinical trials involving over 1,100 patients. The vaccine, based on mRNA technology, combined with the immunotherapy "Ketruda," showed benefits in extending the time patients remain cancer-free and reducing the risk of the cancer spreading to other sites, compared to the standard treatment "Ketruda" alone. These results represent a significant clinical improvement and mark an important step toward offering a new personalized therapy for patients. Negotiations with regulatory authorities have begun in anticipation of potential approval in the near future. This development highlights the possibility that the vaccine could become an effective treatment option for skin cancer, which causes the highest mortality rates among skin cancers, especially after surgical removal of the tumor.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل